ZSP1601 clinical trials
Also written ZSP1601.
- studies test it
- 3
- open now
- 0
- in phase 3
- 0
- first study started
- 2018
How each study uses ZSP1601 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Development codes
- ZSP1601
- 2
Studies by the year they started
3 studies that test it; most in 2018 (1)
| Year | Studies |
|---|---|
| 2018 | 1 |
| 2020 | 1 |
| 2023 | 1 |
Who runs them
Industry 3 · Other 0
Guangdong Raynovent Biotech Co., Ltd (2) · Guangdong Zhongsheng Pharmaceutical Co., Ltd. (1)
Studies
Open first, then newest update. How each study uses ZSP1601 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 3
- A Randomized, Double-blind, Placebo-controlled Study of ZSP1601 in Adult Subjects With Nonalcoholic Steatohepatitis (NASH)Active, not recruitingPhase 2Guangdong Raynovent Biotech Co., LtdNCT05692492Written as ZSP1601
- Tolerability, Efficacy, and PK of ZSP1601 in Patients With Non-Alcoholic Steatohepatitis (NASH)CompletedPhase 1/2Guangdong Raynovent Biotech Co., LtdNCT04140123Written as ZSP1601
- Study in Chinese Healthy Adults to Evaluate the Safety, Tolerability and Pharmacokinetics on ZSP1601, and the Effect of Food on ZSP1601 PharmacokineticsCompletedPhase 1Guangdong Zhongsheng Pharmaceutical Co., Ltd.NCT03392779Written as ZSP1601 25 mg